INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Actinium Pharmaceuticals, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's Iomab-B BLA application and its clinical trial data [3][5]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in Actinium between October 31, 2022, and August 2, 2024, to discuss their legal rights [1]. - A federal securities class action has been filed against Actinium, with a deadline of May 26, 2025, for investors to seek the role of lead plaintiff [3]. Group 2: Allegations Against Actinium - The complaint alleges that Actinium and its executives made false or misleading statements regarding the likelihood of FDA approval for the Iomab-B BLA based on the Sierra Trial data [5]. - It is claimed that the additional analyses provided to the FDA were unlikely to satisfy the agency's guidelines, which could lead to a refusal to review or approve the BLA [5]. Group 3: Stock Price Impact - Following the release of a press statement on August 5, 2024, which indicated the need for an additional clinical trial, Actinium's stock price fell by $3.69, or nearly 60%, closing at $2.48 [6][7].